Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy clinical trials

Explore recruiting patients over 55 with acute myeloid leukemia aml and idh1 mutation in complete remission after intensive chemotherapy clinical trials.

Also recruiting in Europe

Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy trials by city

Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Toronto Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Vancouver Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Montreal Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Calgary Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Edmonton Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Ottawa Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Winnipeg Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Quebec City Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Hamilton Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Kitchener Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in London Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Halifax Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in New York Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Los Angeles Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Chicago Patients Over 55 With Acute Myeloid Leukemia Aml And Idh1 Mutation In Complete Remission After Intensive Chemotherapy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease